Analysts Set Eli Lilly and Company (LLY) Target Price at $88.02

Analysts Set Eli Lilly and Company (LLY) Target Price at $88.02

Eli Lilly and Company (NYSE:LLY) has received a consensus recommendation of “Buy” from the eighteen ratings firms that are presently covering the stock. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $86.53.

Several equities research analysts have issued reports on the company. Zacks Investment Research raised Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $87.00 price target for the company in a report on Friday, February 3rd. Sanford C. Bernstein reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a report on Wednesday, December 7th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $85.00 price target (up previously from $82.00) on shares of Eli Lilly and Company in a report on Wednesday, December 21st. Barclays PLC raised their price target on Eli Lilly and Company from $80.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, February 1st. Finally, Citigroup Inc. reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Tuesday, November 8th.

Shares of Eli Lilly and Company (NYSE:LLY) opened at 77.70 on Friday. The stock has a 50 day moving average of $75.58 and a 200 day moving average of $76.80. The firm has a market cap of $83.30 billion, a P/E ratio of 30.14 and a beta of 0.30. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $83.79.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, January 31st. The company reported $0.95 EPS for the quarter, missing the consensus estimate of $0.98 by $0.03. The company earned $5.76 billion during the quarter, compared to analyst estimates of $5.54 billion. Eli Lilly and Company had a net margin of 12.90% and a return on equity of 24.74%. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.78 EPS. Analysts anticipate that Eli Lilly and Company will post $4.11 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 10th. Shareholders of record on Wednesday, February 15th will be given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.68%. The ex-dividend date of this dividend is Monday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $0.51. Eli Lilly and Company’s payout ratio is currently 79.07%.

In other Eli Lilly and Company news, EVP Derica W. Rice sold 11,162 shares of Eli Lilly and Company stock in a transaction dated Friday, February 3rd. The stock was sold at an average price of $77.14, for a total value of $861,036.68. Following the transaction, the executive vice president now owns 58,443 shares in the company, valued at $4,508,293.02. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Melissa S. Barnes sold 2,093 shares of Eli Lilly and Company stock in a transaction dated Friday, December 16th. The shares were sold at an average price of $82.23, for a total value of $172,107.39. Following the completion of the transaction, the insider now owns 8,169 shares in the company, valued at approximately $671,736.87. The disclosure for this sale can be found here. In the last quarter, insiders sold 455,497 shares of company stock worth $34,193,765. Company insiders own 0.20% of the company’s stock.

Several hedge funds have recently made changes to their positions in the stock. Ronna Sue Cohen raised its stake in shares of Eli Lilly and Company by 0.3% in the third quarter. Ronna Sue Cohen now owns 2,722 shares of the company’s stock worth $218,000 after buying an additional 9 shares during the last quarter. Tarbox Group Inc. raised its stake in shares of Eli Lilly and Company by 0.7% in the third quarter. Tarbox Group Inc. now owns 1,539 shares of the company’s stock worth $124,000 after buying an additional 11 shares during the last quarter. First Citizens Bank & Trust Co. raised its stake in shares of Eli Lilly and Company by 0.3% in the third quarter. First Citizens Bank & Trust Co. now owns 5,920 shares of the company’s stock worth $476,000 after buying an additional 18 shares during the last quarter. Strategic Financial Group LLC raised its stake in shares of Eli Lilly and Company by 0.5% in the third quarter. Strategic Financial Group LLC now owns 3,449 shares of the company’s stock worth $277,000 after buying an additional 18 shares during the last quarter. Finally, Alpha Windward LLC raised its stake in shares of Eli Lilly and Company by 0.9% in the third quarter. Alpha Windward LLC now owns 2,133 shares of the company’s stock worth $171,000 after buying an additional 19 shares during the last quarter. 74.98% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Related posts

Leave a Comment